Ceria Therapeutics
Research - Aurora, Colorado, United States
Ceria Therapeutics Employees
Ceria Therapeutics Senior Management
Ceria Therapeutics Details
Ceria was founded to develop products from a proprietary platform technology to treat life-threatening human diseases characterized by overactive and dysregulated immune responses.Ceria's platform technology consists of a novel active pharmaceutical agent comprised of a regulatory microRNA (miR-146a) conjugated to cerium nanoparticles (CNPs). Like all nanoparticles, CNPs are actively endocytosed by all cells they contact, delivering the miR-146a payload to targeted cells. Multiple high morbidity and life-threatening conditions are characterized by dysregulated immune responses including acute respiratory distress syndrome (ARDS), diabetic foot ulcers (DFU) and ulcerative colitis (UC), representing a US market of $4B. Affected tissues in these conditions all demonstrate reduce miR-146a and are corrected by our candidate drug products.Development to date has been supported by ~$7.5m of nondilutive financing and $500k investment capital. The company is seeking up to $3m in investment capital to contribute to a first-in-man clinical study of one drug product consisting of formulated CNP-miR-146a in DFU.
Ceria Therapeutics Technologies
Load Balancers
Nginx
CMS
WordPress.org
Fonts
Google Font API
Hosting
Blue Host
Other
Mobile Friendly